BHVN — Biohaven Ltd.

Biohaven Pharmaceuticals (BHVN) Q4 2021 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2021 Net Sales: $190 million for NURTEC ODT, a 40% increase from Q3 and a 440% year-over-year growth.
• Full Year 2021 Net Sales: $462.5 million for NURTEC ODT, a 627% increase compared to 2020.
• R&D Expenses (Q4 2021): $76.4 million, up 32% from the prior quarter.
• SG&A Expenses (Q4 2021): $189.3 million, a 66% increase from the previous quarter.
• Cash Position: $367 million in cash and equivalents as of December 2021, with access to approximately $1 billion in liquidity post-collaboration with Pfizer.

2. Strategic Updates and Business Highlights:

• Market Leadership: NURTEC ODT is now the number one prescribed migraine treatment in its class, with over 1.6 million prescriptions since launch.
• Collaboration with Pfizer: A global partnership for rimegepant is underway, with a positive opinion from the CHMP for marketing authorization in the EU.
• Pipeline Expansion: Biohaven announced the acquisition of two new platforms: a Kv7 Ion Channel Activator for epilepsy and Taldefgrobep, a myostatin-targeting asset for spinal muscular atrophy (SMA).
• Regulatory Progress: Anticipated NDA submission for zavegepant in the U.S. and a regulatory submission in China for rimegepant in the second half of 2022.

3. Forward Guidance and Outlook:

• While no formal revenue guidance was provided, analysts speculated on potential NURTEC revenues around $850 million for 2022.
• The company expects modest increases in expenses due to new asset acquisitions but remains focused on maximizing shareholder value and achieving profitability.

4. Bad News, Challenges, or Points of Concern:

• Increased Expenses: Significant increases in R&D and SG&A expenses could raise concerns about the sustainability of profitability.
• Market Competition: The oral CGRP market is growing, but competition from other migraine treatments, including older triptans and new entrants, poses a risk.
• Seasonal Variability: The company noted that typical seasonal changes could impact volume and revenues in Q1 2022.

5. Notable Q&A Insights:

• Commercial Strategy: The company plans to maintain a digital-first approach while gradually increasing in-person sales efforts as the pandemic recedes.
• Pipeline Investment Concerns: Some investors expressed worry that increasing pipeline investments could detract from NURTEC’s value. Management reassured that these investments are strategic and aimed at long-term growth.
• Clinical Trial Focus: For SMA, the company is considering a focus on specific subpopulations, such as type 1, in their clinical trial designs.
• Differentiation of New Assets: Management emphasized the potential of BHV-7000 as a best-in-class Kv7 activator with a favorable side effect profile compared to existing treatments.

Overall, Biohaven demonstrated strong financial performance and strategic advancements in Q4 2021, while also addressing challenges and competitive pressures in the migraine treatment market.